Plasma immune proteome-based risk score predicts survival in advanced gastric cancer treated with PD-1 inhibitors and chemotherapy
Baseline plasma immune proteomics supports a compact, interpretable five-protein risk score that augments clinicopathologic variables for prognostic stratification under PD-1-based chemoimmunotherapy. The model is amenable to targeted assay translation and prospective validation for clinical deployment.
Authors
- Bijuan Chen (ORCID: https://orcid.org/0000-0002-9817-7220)
- Hanchen Zheng
- Lin Le (ORCID: https://orcid.org/0000-0003-3515-7326)
- Sha Huang (ORCID: https://orcid.org/0000-0003-2589-5181)
- Qiaoting Hu
- Ruyu Lin
- Xiaojie Wang
- Zhouwei Zhan
- Zengqing Guo
- Xiaoyan Lin
- Yigui Chen
Institutions
- Fujian Medical University (CN)
- Fujian Provincial Cancer Hospital (CN)
- Union Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-01-12
- DOI
- https://doi.org/10.3389/fimmu.2025.1715993
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Fujian Province